NCT06787482View on ClinicalTrials.gov

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Retinitis Pigmentosa (RP)Age Related Macular DegenerationDiabetic Retinopathy
Interventions
DIETARY_SUPPLEMENT

ACE Retino

1 ml sublingually self administer / 4 times/day for 6 months

Trial Locations (2)

Unknown

RECRUITING

Dr. Seif Clinic, Cairo

!2112

RECRUITING

British Center for Regeerative medicne (Cairo), Giza

All Listed Sponsors
collaborator

European Wellness Academy

INDUSTRY

lead

Ace Cells Lab Limited

INDUSTRY

NCT06787482 - Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies | Biotech Hunter | Biotech Hunter